公司概覽
業務類別 Biotechnology
業務概覽 Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
公司地址 2855 Gazelle Court, Carlsbad, CA, USA, 92010
電話號碼 +1 760 931-9200
傳真號碼 +1 760 268-4922
公司網頁 https://www.ionis.com
員工數量 1402
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Brett P. Monia, PhD Chief Executive Officer and Director 美元 1.01M 26/02/2026
Ms. Elizabeth L. Hougen Executive Vice President, Finance, Principal Accounting Officer and Chief Financial Officer 美元 700.00K 26/02/2026
Mr. Patrick R. O'Neil, Esq. Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary 美元 586.85K 19/02/2025
Ms. Shannon L. Devers Executive Vice President and Chief Human Resources Officer -- 19/02/2025
Mr. Joseph T. Baroldi Executive Vice President and Chief Business Officer -- 19/02/2025
Mr. Kyle Jenne Executive Vice President and Chief Global Product Strategy Officer 美元 446.54K 19/02/2025
Dr. Holly B. Kordasiewicz, PhD Senior Vice President, Neurology -- 12/06/2025
 
董事會成員
董事會 職務 更新日期
Ms. B. Lynne Parshall, Esq.,J.D. Director 26/02/2026
Mr. Joseph H. Wender Lead Independent Director 26/02/2026
Mr. Joseph Klein, III Independent Director 26/02/2026
Dr. Joseph Loscalzo, M.D.,PhD Chairman of the Board 26/02/2026
Ms. Joan E. Herman Independent Director 26/02/2026
Dr. Spencer R. Berthelsen,M.D. Independent Director 26/02/2026
Dr. Michael Hayden, PhD Independent Director 26/02/2026
Dr. Brett P. Monia, PhD Chief Executive Officer and Director 26/02/2026
Mr. Michael J. Yang Independent Director 26/02/2026
Ms. Allene M. Diaz Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:04)
代號 名稱 佔比% 持有日期
ONEQFidelity Nasdaq Composite ETF0.02%27/02/2026
ESGVVanguard ESG US Stock ETF0.02%31/01/2026
FPXFirst Trust US Equity Opportunities ETF0.02%26/02/2026
JMOMJPMorgan US Momentum Factor ETF0.02%27/02/2026
KOMPStt Strt®SPDR®S&PKenshoNwEcosComposETF0.02%27/02/2026
HQLabrdn Life Sciences Investors0.02%31/01/2026
IWDiShares Russell 1000 Value ETF0.02%28/02/2026
VONEVanguard Russell 1000 ETF0.02%31/01/2026
BKMCBNY Mellon US Mid Cap Core Equity ETF0.02%28/02/2026
DFACDimensional US Core Equity 2 ETF0.01%27/02/2026
PBPHPortfolio Bldg Blck Wld Phrm &BtchIdxETF0.01%26/02/2026
NBCRNeuberger Core Equity ETF0.01%28/02/2026
DWASInvesco Dorsey Wright SmallCap Momt ETF0.01%27/02/2026
SMMViShares MSCI USA Sm-Cp Min Vol Fctr ETF0.01%28/02/2026
FFLGFidelity Fundamental Large Cap Gr ETF0.01%27/02/2026
FTQIFirst Trust Nasdaq BuyWrite Income ETF0.01%26/02/2026
VTHRVanguard Russell 3000 ETF0.01%31/01/2026
SCHKSchwab 1000 ETF0.01%28/02/2026
RECSColumbia Research Enhanced Core ETF0.01%04/02/2026
WSMLiShares MSCI World Small-Cap ETF0.01%28/02/2026
  1    2   3    4    5    6    7  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.